Susie Armstrong

Susan M. Armstrong started at Qualcomm working on Globalstar and then early CDMA base station projects. She was a pioneer in bringing internet protocols to the cellular industry, resulting in the first web surfing on a cellular phone in 1997, and Qualcomm’s commercialization of packet data in 1998. Since then she has held various leadership positions, first responsible for the development and commercialization of the all of the software that drives Qualcomm’s chipsets, and then as the head of worldwide Customer Engineering. In addition to her work on Qualcomm’s inventions and new technologies, she has worked extensively with base station makers, carriers, phone and device makers in the US, Asia and Europe to bring those technologies to market.

In 2015, Armstrong has joined Qualcomm’s Government Affairs group, where she brings an engineering and product background the Government Affairs work in worldwide public policy, including intellectual property protection, cyber security, STEM and STEM diversity.

When AI Helps Generate Inventions, Who Is the Inventor?

By Andrei Iancu and Rama Elluru This commentary from the CSIS-SCSP Task Force on IP in the AI Era was originally published in the Special Competitive Studies Project’s Substack on February 15, 2024. With roots in the U.S. constitution, patent rights provide an exclusive property right in new inventions like drugs,
Read More

Standard Essential Patents and European Economic Security

By Kirti Gupta and Chris Borges On April 27, 2023, the European Commission published a draft proposal on standard essential patents (SEPs) seeking to address the perceived lack of transparency and predictability in the licensing of SEPs. The commission proposes the creation of a competence center within the European Union Intellectual
Read More

Proposed Federal Use of March-in Rights Would Weaken American Innovation

By Sujai Shivakumar and Thomas Howell   The Biden administration is considering exercising something called “march-in rights” as a policy prescription to curb drug prices. But as with any prescription, there is a need to weigh efficacy against the side-effects. In this case, there is evidence that the vast majority of
Read More